Executive Committee

Frank Béraud

Frank Béraud,
Chief Executive Officer of Montréal InVivo

Holding more than 25 years of experience in the life sciences sector, Mr. Béraud has particularly acquired a solid expertise in business development. With a background in sales and marketing within multinationals in the field of clinical diagnostic, his career path has led him to assume responsibility for business development for an SME in the domain of biotechnology, in addition to working as a consultant within the industry as well as a technology transfer organization. Mr. Béraud has also worked on managing the policies and strategic development of an industrial association in the life sciences sector before joining Montréal InVivo’s team. Highly socially engaged with schools and the health community, he currently chairs on the board of a community organization working towards the social and economic reintegration of individuals in situations of homelessness in Montreal (Le Sac à Dos). He is also on the administrative board of BioQuébec, a non-profit organization in the life science and technologies sector in Québec.

Martin LeBlanc

Martin LeBlanc,
Chairman of the Board of Montréal InVivo

Martin is co-founder, President and CEO of Caprion Biosciences, a leading provider of specialized proteomics and immune monitoring laboratory research services to the global pharmaceutical and biotechnology industries. He is also a director of numerous private company and not-for-profit boards. Prior to Caprion, Martin was a management consultant for McKinsey & Company as well as co-owner and senior executive of another successful biotech venture, Advanced Bioconcept. Martin earned his bachelor's degree in Economics from the University of Moncton prior to completing an M.A. in Economics and Politics at Oxford University as a Rhodes Scholar.

Jacques Gagné

Jacques Gagné,
Vice-Chairman of the Board of Montréal InVivo

Very active in the Québec scientific environment, Dr. Jacques Gagné has been Chairman of the Boeard of CQIB, the incubator in life sciences. He has also been President of Prix Galien Canada and President of the Scientific Committee of La Fête champêtre of the Armand-Frappier Foundation. He has had a long and fruitful career. He has been Administrator and Vice president of the Ordre des pharmaciens du Québec, President of the Associstion of the Faculties of Pharmacy of Canada as well as President of the Association of Deans of Pharmacy of Canada. He was Director general and founder of the Institute forv Research in Industrial Pharmacy. He served as a consultant for the Ministère de la santé et des services sociaux du Québec. He has been a founding member and Secretary of Pharma Vision Québec. He also was the founding Executive Director of the Frosst Healthcare Foundation and Chairman of the board of Pharmagène and URRMA. He was a Director of Warnex Inc.. He holds a B.Sc. (Pharmacy), an M.Sc and a Ph.D. in Pharmacology from the Université de Montréal. He was granted a Fellowship from the Medical Research of Canada for a post-doctoral training at the Faculty of Pharmacy at the University of California San Francisco. He has been Professor and Dean of the Faculty of Pharmacy at the Université de Montréal. He is an active member of several professional and scientific organizations. He actively participated in the organization of national as well as international meetings. He acts as a consultant to public and private societies, especially in the areas of biotechnology and pharmacy.

Pierre Falardeau

Pierre Falardeau,
Member of the Board of Montréal InVivo

Pierre Falardeau joined Verlyx Pharma in January 2010, as President and Chief Executive Officer. Dr. Falardeau has broad experience in drug development acquired over several years in the field of oncology. He is the founder of Consultation Pharm-Asset Inc., a consultation services in decision-support committed to delivering evidence-based business guidance to support global success in the pharmaceutical and biopharmaceutical industry, including financing strategy, portfolio optimization and product development. From 2002 to 2007, Dr. Falardeau was President and Chief Executive Officer of Ecopia Biosciences Inc., until the merger of Ecopia with Caprion Pharmaceutical to form Thallion Pharmaceuticals, of which Dr. Falardeau became the Chief Operating Officer until 2009. From 1998 to 2002, he held increasingly responsible positions at Æterna-Zentaris, first as Director, Scientific Affairs, then as Vice-President, Scientific Affairs, with a focus in oncology. From 1987 to 1991, Dr. Falardeau did his post-doctoral training at the Howard Hughes Medical Institute at Duke University, in Durham, North Carolina. Dr. Falardeau obtained his PhD in pharmacology and physiology in 1987 at Laval University, in Quebec City. Dr. Falardeau is a member of the board of directors of several companies and organizations in the life sciences sector.

Dr. Marie-Josée Hébert

Dr. Marie-Josée Hébert,
Member of the Board of Montréal InVivo

Dr. Marie-Josée Hébert is Professor of Medicine at the Faculty of Medicine at Université de Montréal, researcher at the CHUM research centre and nephrologist–transplant physician at CHUM. She holds the Shire Chair in Renal Transplantation and Regeneration at the Université de Montréal. Dr Hébert is the co-director of the Canadian National Transplant Research Program (CNTRP). Dr. Hébert has been appointed Vice-rector – Research, Discovery, Creation and Innovation at Université de Montréal in November 2015. As such, she assumes the coordination of all UdeM research activities at the local, national and international levels. Her mandate also includes creation activities which involves many faculties at UdeM.

Cédric Bisson

Cédric Bisson,
Member of the Board of Montréal InVivo

Cédric Bisson has extensive experience across Canada, USA and Europe creating, building and advising businesses in biopharmaceuticals, healthcare and the innovation sector in general. He is passionate about growing Canada as a premier environment for innovation, and during his career has structured and executed over $3 B in transactions in funds and companies. Mr. Bisson is currently partner at Teralys Capital where he focuses on healthcare and life sciences investments, as well as growth opportunities. Teralys Capital is Canada’s largest private innovation-focused investor, financing funds and companies in IT, life sciences, and clean or industrial innovations, from early stage start-ups to expansion, growth and technology buy-outs. He was previously managing partner for life sciences at iNovia Capital in Montreal, Calgary and the USA, a private venture capital firm aimed at entrepreneurship and company building. Prior to this, he spent many years internationally at McKinsey & Company, a global management consulting firm, where he was a leader in the biopharma, healthcare and innovation practices in New York City, Paris, Montreal, and Toronto.

X

Subscribe to industry news

Which mailing list do you want to subscribe?

Flash InVivo
Info InVivo
Mailing list

What is your preferred language ?

French
English